New oral drug could stop blood condition from turning into cancer

NCT ID NCT07435636

First seen Mar 05, 2026 · Last updated May 15, 2026 · Updated 10 times

Summary

This study tests a low-dose oral drug (decitabine with tetrahydrouridine) in 80 people aged 60-85 with a high-risk blood condition called CCUS, which often leads to blood cancer. The drug aims to reduce harmful blood cell mutations and restore normal blood production without the harsh side effects of standard cancer treatments. Participants will take the drug or a placebo for 24 weeks to see if it can safely prevent disease progression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLONAL HEMATOPOIESIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Canberra Health Services

    Canberra, Australian Capital Territory, 2605, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Prince of Wales Hospital

    Randwick, New South Wales, 2031, Australia

    Contact Phone: •••-•••-••••

  • Westmead Hospital

    Westmead, New South Wales, 2145, Australia

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.